Cargando…
58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada
BACKGROUND: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical manage...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586112/ http://dx.doi.org/10.1093/pch/pxac100.057 |
_version_ | 1784813628346597376 |
---|---|
author | Piché-Renaud, Pierre-Philippe Panetta, Luc Farrar, Daniel Hepburn, Charlotte Moore Drouin, Olivier Papenburg, Jesse Salvadori, Marina Laffin-Thibodeau, Melanie Kakkar, Fatima Morris, Shaun |
author_facet | Piché-Renaud, Pierre-Philippe Panetta, Luc Farrar, Daniel Hepburn, Charlotte Moore Drouin, Olivier Papenburg, Jesse Salvadori, Marina Laffin-Thibodeau, Melanie Kakkar, Fatima Morris, Shaun |
author_sort | Piché-Renaud, Pierre-Philippe |
collection | PubMed |
description | BACKGROUND: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical management and public health interventions. OBJECTIVES: The objective of this study was to describe the clinical manifestations, disease severity, and characteristics associated with hospitalization among infants infected with the initial strains of SARS-CoV-2. DESIGN/METHODS: This is a nationwide prospective observational study using the infrastructure of the Canadian Paediatric Surveillance Program. All cases of infants aged <1 year of age with microbiologically confirmed SARS-CoV-2 infection were reported from April 8th 2020 to May 31st 2021, and were classified by disease severity and primary cause of hospitalization. Multivariable logistic regression was performed to identify infants' characteristics associated with hospitalization. RESULTS: A total of 531 cases were reported, including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19. Amongst all cases with SARS-CoV-2 infection, the most common presenting symptoms included fever (66.5%), coryza (47.1%), cough (37.3%) and decreased oral intake (25.0%). In our main analysis, infants with a comorbid condition had higher odds of hospitalization compared to infants with no comorbid conditions, and infants <1 month had higher odds of hospitalization than infants aged 1-3 months (Table). In total, 20 infants (3.8%) met criteria for severe disease. CONCLUSION: We describe one of the largest cohorts of infants with SARS-CoV-2 infection. Overall, severe COVID-19 in this age group is uncommon with most infants having mild disease. Comorbid conditions and younger age were associated with COVID-19-related hospitalization amongst infants. [Image: see text] |
format | Online Article Text |
id | pubmed-9586112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95861122022-11-04 58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada Piché-Renaud, Pierre-Philippe Panetta, Luc Farrar, Daniel Hepburn, Charlotte Moore Drouin, Olivier Papenburg, Jesse Salvadori, Marina Laffin-Thibodeau, Melanie Kakkar, Fatima Morris, Shaun Paediatr Child Health Abstract / Résumés BACKGROUND: There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical management and public health interventions. OBJECTIVES: The objective of this study was to describe the clinical manifestations, disease severity, and characteristics associated with hospitalization among infants infected with the initial strains of SARS-CoV-2. DESIGN/METHODS: This is a nationwide prospective observational study using the infrastructure of the Canadian Paediatric Surveillance Program. All cases of infants aged <1 year of age with microbiologically confirmed SARS-CoV-2 infection were reported from April 8th 2020 to May 31st 2021, and were classified by disease severity and primary cause of hospitalization. Multivariable logistic regression was performed to identify infants' characteristics associated with hospitalization. RESULTS: A total of 531 cases were reported, including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19. Amongst all cases with SARS-CoV-2 infection, the most common presenting symptoms included fever (66.5%), coryza (47.1%), cough (37.3%) and decreased oral intake (25.0%). In our main analysis, infants with a comorbid condition had higher odds of hospitalization compared to infants with no comorbid conditions, and infants <1 month had higher odds of hospitalization than infants aged 1-3 months (Table). In total, 20 infants (3.8%) met criteria for severe disease. CONCLUSION: We describe one of the largest cohorts of infants with SARS-CoV-2 infection. Overall, severe COVID-19 in this age group is uncommon with most infants having mild disease. Comorbid conditions and younger age were associated with COVID-19-related hospitalization amongst infants. [Image: see text] Oxford University Press 2022-10-21 /pmc/articles/PMC9586112/ http://dx.doi.org/10.1093/pch/pxac100.057 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Canadian Paediatric Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com https://academic.oup.com/pages/standard-publication-reuse-rightsThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights) |
spellingShingle | Abstract / Résumés Piché-Renaud, Pierre-Philippe Panetta, Luc Farrar, Daniel Hepburn, Charlotte Moore Drouin, Olivier Papenburg, Jesse Salvadori, Marina Laffin-Thibodeau, Melanie Kakkar, Fatima Morris, Shaun 58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada |
title | 58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada |
title_full | 58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada |
title_fullStr | 58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada |
title_full_unstemmed | 58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada |
title_short | 58 Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada |
title_sort | 58 clinical manifestations and disease severity of sars-cov-2 infection among infants in canada |
topic | Abstract / Résumés |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586112/ http://dx.doi.org/10.1093/pch/pxac100.057 |
work_keys_str_mv | AT picherenaudpierrephilippe 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT panettaluc 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT farrardaniel 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT hepburncharlottemoore 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT drouinolivier 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT papenburgjesse 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT salvadorimarina 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT laffinthibodeaumelanie 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT kakkarfatima 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada AT morrisshaun 58clinicalmanifestationsanddiseaseseverityofsarscov2infectionamonginfantsincanada |